Cargando…
A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467159/ https://www.ncbi.nlm.nih.gov/pubmed/25605255 |
_version_ | 1782376338025349120 |
---|---|
author | Cao, Hui-Hui Zhang, Shi-Yi Shen, Jin-Hui Wu, Zhi-Yong Wu, Jian-Yi Wang, Shao-Hong Li, En-Min Xu, Li-Yan |
author_facet | Cao, Hui-Hui Zhang, Shi-Yi Shen, Jin-Hui Wu, Zhi-Yong Wu, Jian-Yi Wang, Shao-Hong Li, En-Min Xu, Li-Yan |
author_sort | Cao, Hui-Hui |
collection | PubMed |
description | Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches. |
format | Online Article Text |
id | pubmed-4467159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-44671592015-06-22 A three-protein signature and clinical outcome in esophageal squamous cell carcinoma Cao, Hui-Hui Zhang, Shi-Yi Shen, Jin-Hui Wu, Zhi-Yong Wu, Jian-Yi Wang, Shao-Hong Li, En-Min Xu, Li-Yan Oncotarget Clinical Research Paper Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches. Impact Journals LLC 2014-12-31 /pmc/articles/PMC4467159/ /pubmed/25605255 Text en Copyright: © 2015 Cao et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Cao, Hui-Hui Zhang, Shi-Yi Shen, Jin-Hui Wu, Zhi-Yong Wu, Jian-Yi Wang, Shao-Hong Li, En-Min Xu, Li-Yan A three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
title | A three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
title_full | A three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
title_fullStr | A three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
title_full_unstemmed | A three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
title_short | A three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
title_sort | three-protein signature and clinical outcome in esophageal squamous cell carcinoma |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467159/ https://www.ncbi.nlm.nih.gov/pubmed/25605255 |
work_keys_str_mv | AT caohuihui athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT zhangshiyi athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT shenjinhui athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT wuzhiyong athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT wujianyi athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT wangshaohong athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT lienmin athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT xuliyan athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT caohuihui threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT zhangshiyi threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT shenjinhui threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT wuzhiyong threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT wujianyi threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT wangshaohong threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT lienmin threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma AT xuliyan threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma |